Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Trial of S-1 Versus S-1 plus Oxaliplatin (Sox) in Patients with Gemcitabine Refractory Pancreatic Cancer

Trial Profile

Randomized Phase II Trial of S-1 Versus S-1 plus Oxaliplatin (Sox) in Patients with Gemcitabine Refractory Pancreatic Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxaliplatin (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Adenosquamous carcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Yakult Honsha
  • Most Recent Events

    • 06 Jun 2017 Results of pooled analysis of three studies including this study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2013 According to a Yakult Honsha media release, the company has submitted supplemental new drug applications relating to an additional indication for pancreatic cancer, with respect to its products, Campto (40mg and 100mg), Elplat (50mg, 100mg and 200mg), and Levofolinate [Yakult] (25mg and 100mg), to the Japanese Ministry of Health, Labor and Welfare (MHLW).
    • 30 Oct 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top